PROCEPT BioRobotics Corporation $PRCT Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. lessened its holdings in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 2.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 858,831 shares of the company’s stock after selling 17,532 shares during the period. Baillie Gifford & Co. owned approximately 1.54% of PROCEPT BioRobotics worth $30,652,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Vega Investment Solutions raised its stake in shares of PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after buying an additional 265 shares during the last quarter. JTC Employer Solutions Trustee Ltd acquired a new stake in PROCEPT BioRobotics during the third quarter worth about $30,000. AlphaQuest LLC grew its holdings in PROCEPT BioRobotics by 1,262.5% during the second quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock worth $63,000 after acquiring an additional 1,010 shares during the period. CWM LLC raised its position in PROCEPT BioRobotics by 40.7% during the second quarter. CWM LLC now owns 1,228 shares of the company’s stock valued at $71,000 after acquiring an additional 355 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its holdings in PROCEPT BioRobotics by 90.7% in the second quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock valued at $98,000 after acquiring an additional 810 shares during the period. 89.46% of the stock is owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Price Performance

PROCEPT BioRobotics stock opened at $29.13 on Friday. The company has a fifty day simple moving average of $32.19 and a 200-day simple moving average of $37.76. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -19.04 and a beta of 0.99. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14. PROCEPT BioRobotics Corporation has a 52-week low of $27.80 and a 52-week high of $76.40.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The firm had revenue of $83.33 million for the quarter, compared to analyst estimates of $80.78 million. During the same period in the previous year, the business posted ($0.40) earnings per share. PROCEPT BioRobotics’s quarterly revenue was up 42.6% on a year-over-year basis. On average, equities analysts anticipate that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on PRCT. Bank of America restated a “neutral” rating and issued a $38.00 price objective (down previously from $55.00) on shares of PROCEPT BioRobotics in a research report on Monday, December 8th. Morgan Stanley decreased their target price on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a research note on Tuesday, December 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday. Jefferies Financial Group upgraded shares of PROCEPT BioRobotics from a “hold” rating to a “strong-buy” rating in a research report on Friday, December 12th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $50.00 price objective (down previously from $55.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $53.40.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.